Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Nov. 2025)
08:15am, Saturday, 01'st Nov 2025
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
Medical Stocks To Watch Now – October 30th
05:47am, Saturday, 01'st Nov 2025
Eli Lilly and Company, UnitedHealth Group, and Pfizer are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies
Pfizer sues to block Novo Nordisk's bid for Metsera in high-stakes pharma clash
05:15am, Saturday, 01'st Nov 2025
Pfizer has escalated its fight for obesity biotech Metsera by filing suit against both Metsera and Novo Nordisk in the Delaware Court of Chancery on October 31. The litigation challenges Novo's bombsh
Metsera Issues Statement in Response to Litigation
06:24pm, Friday, 31'st Oct 2025
NEW YORK , Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer: "
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
05:26pm, Friday, 31'st Oct 2025
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused company.
Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera
05:12pm, Friday, 31'st Oct 2025
The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.
Pfizer sues Metsera, Novo Nordisk over breach of merger deal
04:43pm, Friday, 31'st Oct 2025
Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
04:37pm, Friday, 31'st Oct 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit
Pfizer gets US antitrust clearance for Metsera deal
03:55pm, Friday, 31'st Oct 2025
Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera.
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
03:50pm, Friday, 31'st Oct 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improveme
Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?
12:20pm, Friday, 31'st Oct 2025
Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.
How Pfizer Stock Can Rebound
08:40am, Friday, 31'st Oct 2025
Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer.
Pfizer could hold a Trump card in its bid for Metsera
06:02am, Friday, 31'st Oct 2025
U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm Metsera, analyst
Novo Nordisk changes tack with bold raid on Pfizer obesity deal
02:19pm, Thursday, 30'th Oct 2025
Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market unde
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
01:13pm, Thursday, 30'th Oct 2025
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
